Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Revenue of $7.6 million for Q1 2026, down 90.38% year-over-year from $78.9 million in Q1 2025, and down 99.28% quarter-over-quarter from $1.0 billion in Q4 2025.
Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Revenue for 13 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 90.38% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 398.27% YoY), while the FY2025 annual figure was $1.3 billion, up 339.54% from the prior year.
- Revenue slipped to $7.6 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Revenue topped out at $1.0 billion in Q4 2025 and bottomed at -$55.1 million in Q2 2024.
- Historically, Revenue has averaged $122.9 million across 5 years, with a median of $66.6 million in 2023.
- Annual changes were most pronounced in 2024 — Revenue slumped 184.3% — and 2025, when it surged 8432.91%.
- Lakefront Biotherapeutics' Revenue stood at $184.4 million in 2022, then plunged by 34.48% to $120.8 million in 2023, then sank by 89.83% to $12.3 million in 2024, then soared by 8432.91% to $1.0 billion in 2025, then tumbled by 99.28% to $7.6 million in 2026.
- Business Quant data shows LKFT's Revenue at $7.6 million in Q1 2026, $1.0 billion in Q4 2025, and $83.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 7.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.59 Mn |
| Dec 31, 2025 | 1.05 Bn |
| Sep 30, 2025 | 83.15 Mn |
| Jun 30, 2025 | 73.94 Mn |
| Mar 31, 2025 | 78.87 Mn |
| Dec 31, 2024 | 12.29 Mn |
| Sep 30, 2024 | 207.44 Mn |
| Jun 30, 2024 | -55.10 Mn |
| Mar 31, 2024 | 67.82 Mn |
| Dec 31, 2023 | 120.83 Mn |
| Sep 30, 2023 | 66.60 Mn |
| Jun 30, 2023 | 65.36 Mn |
| Mar 31, 2023 | 62.87 Mn |
| Dec 31, 2022 | 184.42 Mn |
| Sep 30, 2022 | 25.30 Mn |
| Jun 30, 2022 | 22.40 Mn |
| Mar 31, 2022 | 16.17 Mn |
| Dec 31, 2021 | 261.15 Mn |
| Sep 30, 2021 | 7.19 Mn |
| Jun 30, 2021 | 168.32 Mn |